loading page

From PurUUpurU to Cytokine Storm to Hyperviscosity, Thrombosis and Other Complications of Coronavirus Disease 2019
  • +2
  • Gregory Sloop,
  • Brent Ryckman,
  • Gheorghe Pop,
  • Joseph Weidman,
  • John St. Cyr
Gregory Sloop
Author Profile
Brent Ryckman
University of Montana Missoula
Author Profile
Gheorghe Pop
Radboud University Medical Center
Author Profile
Joseph Weidman
Author Profile
John St. Cyr
Jacqmar, Inc.
Author Profile


Background: Severe coronavirus disease 2019 (COVID-19) is associated with pathological elevations of tumor necrosis factor-alpha (TNF-ɑ) and interleukin 6 (IL-6). These cause extreme elevations of the acute phase reactant fibrinogen and plasma viscosity. Severe COVID-19 is also associated with poorly understood complications including a high incidence of arterial and venous thrombosis despite prophylactic anticoagulation, silent hypoxemia, pulmonary microvascular thrombosis, excess neutrophil extracellular trap formation, encephalopathy, and cardiac dysfunction. Aims: To investigate the cause of this pathological inflammatory response, the authors determined the number of purine-uridine-uridine-purine-uridine (purUUpurU) motifs in the genomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other RNA viruses. This motif is the precursor to the oligonucleotide which is the minimal motif required to activate inflammation via toll-like receptor 8 (TLR8). A genome containing the same nucleotides in SARS-CoV-2 in random order was used as a control. Result: PurUUpurU occurred 2.8 times more often in the actual SARS-CoV-2 genome than the randomized genome. The number of purUUpurU motifs correlates with the severity of the acute illnesses caused by the RNA viruses examined, except for influenza A. Conclusion: Hyperactivation of TLR8 mediated inflammation by purUUpurU may cause pathological inflammation in COVID-19. Marked elevations of TNF-ɑ, IL-6, and fibrinogen will cause erythrocyte aggregation and increase blood viscosity. This promotes thrombosis and decreases tissue perfusion. Therapeutic plasmapheresis reduces blood hyperviscosity and should be used in severe COVID-19. To date, use of this therapy has only been reported in COVID-19 associated thrombosis.

Peer review status:UNDER REVIEW

02 Feb 2021Submitted to International Journal of Clinical Practice
03 Feb 2021Assigned to Editor
03 Feb 2021Submission Checks Completed
19 Feb 2021Reviewer(s) Assigned